2016
DOI: 10.1002/term.2254
|View full text |Cite
|
Sign up to set email alerts
|

A reproducible method for the isolation and expansion of ovine mesenchymal stromal cells from bone marrow for use in regenerative medicine preclinical studies

Abstract: The use of multipotent mesenchymal stromal cells (MSCs) as candidate medicines for treating a variety of pathologies is based on their qualities as either progenitors for the regeneration of damaged tissue or producers of a number of molecules with pharmacological properties. Preclinical product development programmes include the use of well characterized cell populations for proof of efficacy and safety studies before testing in humans. In the field of orthopaedics, an increasing number of translational studi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
26
0

Year Published

2017
2017
2020
2020

Publication Types

Select...
4
2
1

Relationship

4
3

Authors

Journals

citations
Cited by 20 publications
(27 citation statements)
references
References 24 publications
1
26
0
Order By: Relevance
“…Bone marrow waste material is available from elective knee and hip surgery or major amputations and moreover could be gained from voluntary crista iliaca punctures. Isolation procedures are similar as compared to methods from other species like dog , horse , or sheep and aim at enrichment of MSC from the mononuclear cell fraction. In rodents, the isolation procedure is modified, taking into account the low amount of bone marrow available at all.…”
Section: Msc Availability and Maintenancementioning
confidence: 99%
“…Bone marrow waste material is available from elective knee and hip surgery or major amputations and moreover could be gained from voluntary crista iliaca punctures. Isolation procedures are similar as compared to methods from other species like dog , horse , or sheep and aim at enrichment of MSC from the mononuclear cell fraction. In rodents, the isolation procedure is modified, taking into account the low amount of bone marrow available at all.…”
Section: Msc Availability and Maintenancementioning
confidence: 99%
“…Although systemic infusion of MSC has been shown to increase bone growth and repair in clinical trials [53][54][55], administered cells engraft poorly. In this line, previous in vivo studies carried out by our group in which ovine eGFP+ BM-MSC were infused in an ovine model of osteonecrosis of the femoral head demonstrated the presence of non-stained eGFP osteocytes in newly formed bone matrix, suggesting that contribution of MSC lies also in paracrine signalling that activate and recruit host osteoblasts to the bone repair areas [56]. Increasing evidence have shown that nanosized, membrane-encapsulated EVs are one of the most active MSCs' secreted factors [25].…”
Section: Discussionmentioning
confidence: 66%
“…With respect to the scaffold, commercial particulated deantigenized bone matrix from human cadaveric donors was used as a natural osteoinductive and osteoconductive agent. This approach was preferred provided that cells attached to the scaffold would persist longer in the site of administration, as was demonstrated in a sheep model of avascular osteonecrosis (Caminal et al ., ). Animals included in the preclinical study weighted 37.1 ± 3.5 kg (range 30.4–41.8 kg, n = 16).…”
Section: Resultsmentioning
confidence: 97%
“…Both ovine and human tissues were harvested, fixed in 4% formalin at room temperature, decalcified in 5% formic acid (Decalcifier I; Surgipath Canada Inc., Winnipeg, Canada), and embedded in paraffin for subsequent histological and immunohistochemical procedures (Caminal et al ., ; Oliver‐Vila et al ., ). Microtome sections 4 μm thick were either stained with H&E or immunostained for the detection of macrophages (CD68, KP‐1; Dako, Glostrup, Denmark), and vessels (endothelial cells, CD31, JC70A, Dako), as reported elsewhere (Gomez‐Puerta et al ., ).…”
Section: Methodsmentioning
confidence: 97%